Clinical Trials
46 trialsCD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Tongji Hospital
IASO207 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies
Peking University People's Hospital
AB154 Combined With AB122 for Recurrent Glioblastoma
Yale University
CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command
CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
Affiliated Hospital to Academy of Military Medical Sciences
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Children's Hospital Medical Center, Cincinnati
SL4903
Institute of Hematology & Blood Diseases Hospital, China
Engineered T-Cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors
Beijing GoBroad Hospital
Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors
The First Affiliated Hospital with Nanjing Medical University
Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
University of Iowa
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University
Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)
Duke University
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Nationwide Children's Hospital
Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas
University of California, San Francisco
CAR19BCMA
Chinese PLA General Hospital
CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)
Institute of Hematology & Blood Diseases Hospital, China
A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital of Nanchang University
High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
Eye & ENT Hospital of Fudan University
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
Thomas Jefferson University
Pilot Trial for Treatment of Recurrent Glioblastoma
AHS Cancer Control Alberta
Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors
The First Affiliated Hospital with Nanjing Medical University
Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients
Hrain Biotechnology Co., Ltd.
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
The General Hospital of Western Theater Command
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
Shanghai Cell Therapy Group Co.,Ltd
a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
Shanghai Changzheng Hospital
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
Guangdong Second Provincial General Hospital
BGT007H Cells for the Treatment of Refractory Digestive System Tumors
The Affiliated Hospital of Xuzhou Medical University
BGT007 Cells for the Treatment of Refractory Digestive System Tumors
The Affiliated Hospital of Xuzhou Medical University
JY231 Injection in the Treatment of Relapsed or Refractory B-cell Lymphoma
Guangdong Second Provincial General Hospital
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Application of Palliative Treatment in Children With Brain Stem Glioma and Recurrent High-grade Tumors in the Central Nervous System With the Nanomaterial NPt-Ca
Hospital Infantil de Mexico Federico Gomez
An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer
Shanghai Pudong Hospital
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
Zhejiang University
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
Zhejiang University
FDG and FDOPA PET Demonstration of Functional Brain Abnormalities
University of Virginia
The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
Shanghai Longyao Biotechnology Inc., Ltd.
γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
Institute of Hematology & Blood Diseases Hospital, China
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies
Shandong University
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
Mayo Clinic
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Zhejiang University
BCMA CAR-T
The Pregene (ShenZhen) Biotechnology Company, Ltd.
Study of BCMA CAR-T in Multiple Myeloma
Allife Medical Science and Technology Co., Ltd.
CD123 Redirected Autologous T Cells for AML
University of Pennsylvania
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
Case Comprehensive Cancer Center